成都普瑞眼科医院集团股份有限公司 独立董事2024年度述职报告 （CHEN PENGHUI） 2024年度，本人作为成都普瑞眼科医院集团股份有限公司（以下简称"公 司"）第三届董事会独立董事，严格按照《中华人民共和国公司法》《上市公 司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法律法规及 《公司章程》《独立董事工作细则》等公司相关规定和要求，本着严谨认真、 勤勉尽责、诚实独立的原则，通过积极参加董事会和股东大会谨慎审核公司提 交的各项议案，发挥董事会专门委员会、独立董事专门会议的作用等方式忠实 履行了独立董事的职责和义务，切实维护了公司整体利益和全体股东的合法权 益。现将本人2024年度工作情况汇报如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人CHEN PENGHUI（陈鹏辉），1972年出生，美国国籍，硕士学历。曾任 尚华医药集团首席运营官、首席财务官、总裁，中国光大控股有限公司医疗基 金任负责人、董事、总经理，红杉资本中国基金合伙人。现任博睿瑜业（上海） 股权投资管理有限公司创始合伙人、公司独立董事。 ...

第三条 公司的关联交易应当遵循以下基本原则： （一）平等、自愿、等价、有偿的原则； （二）公平、公正、公开的原则； （三）关联方如在股东会上享有表决权，除特殊情况外，均应对关联交易事 项回避表决； （四）与关联方有任何利害关系的董事，在董事会就该关联交易事项进行表 决时，应当回避；若因特殊情况无法回避，应按本制度规定程序参与表决，但必 须单独出具声明； （五）公司董事会应当根据客观标准判断该关联交易是否对公司有利，必要 时应聘请专业评估机构或独立财务顾问发表意见。 普瑞眼科医院集团股份有限公司 关联交易管理制度 第一章 总则 第一条 为保证公司与关联方之间发生的关联交易符合公平、公正、公开的 原则，确保公司关联交易行为不损害公司和股东的利益，特别是中小投资者的合 法利益，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《深圳 证券交易所创业板股票上市规则》（以下称"《上市规则》"）《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《普瑞眼科医 院集团股份有限公司章程》（以下称"《公司章程》"）及其他有关法律、法规 和规范性文件的规定，特制定本制度。 第二条 公司的关联交易是 ...

普瑞眼科医院集团股份有限公司 股东会议事规则 第一章 总则 第一条 为规范普瑞眼科医院集团股份有限公司（以下称"公司"）的行为， 保证股东依法行使职权，根据《中华人民共和国公司法》（以下称"《公司法》"）、 《中华人民共和国证券法》（以下称"《证券法》"）、《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》的规定，并参 照《上市公司治理准则》和《上市公司股东会规则》以及其他法律、行政法规， 制订本规则。 第二条 公司应当严格按照法律、行政法规、《公司章程》的相关规定召开股 东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第二章 股东会的一般规定 第四条 股东会是公司的权力机构，依法行使下列职权： 1 （一） 选举和更换董事，决定有关董事的报酬事项； （二） 审议批准董事会的报告； （三） 审议批准公司的利润分配方案和弥补亏损方案； （四） 对公司增加或者减少注册资本作出决议； （五） 对发行公司债券作出 ...

第一条 为规范公司的重大经营及投资决策程序，建立系统完善的重大经营 及投资决策机制，确保决策的科学、规范、透明，有效防范各种风险，保障公司 和股东的利益，根据《中华人民共和国公司法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律、法规及《普瑞眼科医院集团股份有限公司章程》（以下简 称"《公司章程》"）的规定，制定本制度。 第二条 重大经营与投资决策管理的原则： （一）遵守国家法律、法规，符合国家产业政策； （二）符合公司发展战略及经营规划，突出公司主营业务； （三）严格执行决策程序，科学决策，规范管理，控制风险。 普瑞眼科医院集团股份有限公司 重大经营与投资决策管理制度 第一章 总则 1 （五）租入或者租出资产； 第三条 公司各部门为公司重大经营决策的职能部门，负责重大经营事项的 承揽、论证、实施和监控；公司经理层负责管理公司投资事项，负责公司投资项 目的规划、论证、监控以及年度投资计划的编制和实施过程的宏观监控。 第二章 决策范围 第四条 依据本制度进行的重大经营及投资事项包括： （一）购买或者出售资产（不含购买与日常经营相关的原 ...

第五条 公司财务部为公司融资及对外担保的日常管理部门。 第二章 公司融资事项的审批 普瑞眼科医院集团股份有限公司 融资与对外担保管理制度 第一章 总则 第一条 为了规范公司融资和对外担保管理，有效控制公司融资风险和对外 担保风险，保护公司财务安全和投资者的合法权益，根据《中华人民共和国公司 法》、《中华人民共和国证券法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《上市公司监管指引第 8 号——上市公司资金 往来、对外担保的监管要求》等法律、行政法规和规范性文件及《普瑞眼科医院 集团股份有限公司章程》（以下简称"《公司章程》"）的相关规定，制定本制度。 第二条 本制度所称融资，是指公司向以银行为主的金融机构进行间接融资 的行为，主要包括综合授信、流动资金贷款和固定资产贷款、信用证融资、票据 融资和开具保函等形式。 第三条 本制度所称对外担保，是指公司及其控股子公司以第三人身份为他 人提供保证、抵押、质押或其他形式的担保，包括公司为其控股子公司提供的担 保。公司控股子公司对于向公司合并报表范围之外的主体提供担保的，应视同公 司提供担保，公司应按照制度规定执行。 第四条 公司融资 ...

普瑞眼科医院集团股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为进一步完善普瑞眼科医院集团股份有限公司（下称"公司"） 内幕信息管理行为，加强内幕信息保密工作，维护信息披露的公平，根据《中华 人民共和国公司法》《中华人民共和国证券法》（以下称"《证券法》"）、《深 圳证券交易所创业板股票上市规则》《上市公司信息披露管理办法》《上市公司 监管指引第 5 号--上市公司内幕信息知情人登记管理制度》《深圳证券交易所上 市公司自律监管指引第 5 号——信息披露事务管理》等有关法律、法规及规范性 文件及《普瑞眼科医院集团股份有限公司章程》（以下称"《公司章程》"）、 《普瑞眼科医院集团股份有限公司信息披露管理制度》（下称"《公司信息披露 管理制度》"）的规定，结合公司实际情况，制定本制度。 第二条 董事会是公司内幕信息的管理机构，董事长为公司内幕信息保密 的主要负责人，董事会秘书具体负责内幕信息知情人登记管理工作。 第三条 公司证券部为公司内幕信息监督、管理、登记、披露及备案的日 常工作部门，具体负责公司内幕信息的日常管理工作。 对外报道传送的文件、电子存储设备等涉及内幕信息及信息披露内容的资 料，须 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥742,251,316.24, representing a year-on-year increase of 9.82% compared to ¥675,882,973.16 in the same period last year[5] - Net profit attributable to shareholders was ¥27,279,356.63, marking a significant increase of 61.18% from ¥16,924,936.43 in the previous year[5] - Basic and diluted earnings per share rose to ¥0.18, reflecting a growth of 63.64% compared to ¥0.11 in the same quarter last year[5] - Net profit for the current period was ¥28,776,862.83, representing a 51.5% increase from ¥19,042,640.10 in the previous period[20] - Earnings per share (EPS) for the current period was ¥0.18, compared to ¥0.11 in the previous period, indicating a 63.6% increase[21] Cash Flow - The net cash flow from operating activities increased by 54.87% to ¥194,676,885.40, up from ¥125,706,825.28 in Q1 2024[5] - Cash inflow from operating activities totaled ¥755,768,471.98, up from ¥679,993,838.41, marking an increase of 11.1%[23] - The net cash flow from operating activities was $194.68 million, an increase from $125.71 million in the previous period, reflecting a growth of 55%[24] - The net cash flow from investing activities improved by 33.81%, decreasing to -¥129,970,029.96 from -¥196,363,723.78 in the previous year[8] - The company reported a net cash outflow from investing activities of $129.97 million, an improvement from a net outflow of $196.36 million previously[24] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥4,697,051,407.54, a 2.15% increase from ¥4,598,026,724.34 at the end of the previous year[5] - Current assets increased to CNY 1,042,289,047.66 from CNY 869,259,065.91, representing a growth of about 19.93%[15] - Total liabilities rose to ¥2,539,477,942.20, compared to ¥2,476,861,122.42, an increase of 2.5%[18] - Total equity attributable to shareholders reached ¥2,134,699,722.16, up from ¥2,101,497,552.89, a growth of 1.6%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,024[10] - The largest shareholder, Chengdu Puri Century Investment Co., Ltd., holds a 35.91% stake, amounting to 53,729,585 shares, with 20,541,200 shares pledged[10] - The company reported a total of 3,603,810 shares held by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, making it one of the top shareholders[12] - The company has a total of 1,900,073 shares held by Industrial and Commercial Bank of China - Rongtong Health Industry Flexible Allocation Mixed Securities Investment Fund, indicating significant institutional interest[12] Operating Costs and Expenses - Total operating costs amounted to ¥690,187,707.10, up from ¥636,079,700.34, reflecting a rise of 8.5%[19] - Research and development expenses were ¥2,461,386.01, slightly up from ¥2,410,662.58, indicating a focus on innovation[20] - The company reported a decrease in tax expenses to ¥23,086,518.32 from ¥17,934,906.28, a reduction of 28.5%[20] - Cash outflows for employee compensation were $270.18 million, up from $237.42 million, representing an increase of 13.8%[24] Investment Activities - Total cash outflow from investing activities amounted to $299.32 million, compared to $196.39 million previously, indicating a significant increase in investment spending[24] - The cash inflow from investment activities was $169.35 million, significantly higher than $25.50 million in the previous period, marking a substantial increase[24]

Financial Performance - The company's operating revenue for 2024 was approximately ¥2.68 billion, a decrease of 1.46% compared to ¥2.72 billion in 2023[25]. - The net profit attributable to shareholders for 2024 was approximately -¥101.86 million, representing a decline of 138.02% from ¥267.91 million in 2023[25]. - The cash flow from operating activities for 2024 was approximately ¥382.43 million, down 37.76% from ¥614.46 million in 2023[25]. - The basic earnings per share for 2024 was -¥0.68, a decrease of 137.99% compared to ¥1.79 in 2023[25]. - Total assets at the end of 2024 were approximately ¥4.60 billion, a decrease of 4.51% from ¥4.82 billion at the end of 2023[25]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥2.10 billion, down 8.30% from ¥2.29 billion at the end of 2023[25]. - The company reported a quarterly operating revenue of ¥675.88 million in Q1 2024, with a decline in revenue to ¥541.58 million in Q4 2024[27]. - The net profit attributable to shareholders in Q4 2024 was -¥117.70 million, following a positive net profit in the first two quarters[27]. - The company experienced a significant drop in net profit after deducting non-recurring gains and losses, with a figure of -¥85.22 million for 2024 compared to ¥197.81 million in 2023[25]. - The weighted average return on equity for 2024 was -4.65%, a decrease of 16.86% from 12.21% in 2023[25]. - The company reported a non-operating loss of approximately ¥16.64 million in 2024, a significant decrease from a profit of ¥70.1 million in 2023[32]. Market and Industry Trends - In 2024, the company's revenue from refractive and optical projects experienced a slight decline due to a slowdown in overall demand and intensified industry competition[4]. - The implementation of national centralized procurement policies for cataract artificial lenses starting May 2024 has put pressure on the company's cataract project revenue[4]. - The company is positioned in a growing ophthalmic medical service market, with a significant increase in myopia prevalence from 39.2% in 2016 to 47.1% in 2020[36]. - The cataract surgery penetration rate in China remains low despite rapid growth in the number of surgeries over the past decade, indicating room for further market expansion[37]. - The overall myopia rate among children and adolescents in China is 51.9%, highlighting a critical need for effective prevention measures[36]. - The National Health Commission's "14th Five-Year" plan aims for a 90% coverage rate for eye health checks among children aged 0-6 by 2025, which will enhance market opportunities[37]. - The market for myopia prevention products is expected to grow as public awareness increases, with products like orthokeratology lenses gaining traction[36]. Strategic Initiatives and Investments - The company has accelerated its investment expansion, opening multiple new hospitals in 2022, 2023, and 2024, including locations in Kunming, Nanchang, and Shanghai[5][6]. - New hospitals are currently in the market cultivation phase, leading to slower revenue growth and increased operational costs, including depreciation and labor expenses[6]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[7]. - The company is focusing on enhancing service capabilities in pediatric myopia prevention and elderly eye disease treatment as part of its strategic initiatives[37]. - The company is committed to adapting to the evolving healthcare landscape, leveraging technological advancements to meet the rising demand for personalized eye care solutions[35]. - The company is actively responding to the national strategy for myopia prevention and control, establishing a personalized vision management system[56]. - The company has established a "full-cycle eye health service system" focusing on pre-diagnosis, diagnosis, and post-diagnosis management[47]. Technological Advancements - AI technology is rapidly penetrating the eye care sector, optimizing diagnosis and treatment processes, and facilitating a shift towards intelligent and precise medical services[44]. - AI algorithms are being utilized for real-time monitoring of eye pressure and personalized rehabilitation plans for cataract patients, significantly improving post-operative satisfaction[45]. - The introduction of AI in operational areas is enhancing scheduling, cost monitoring, and patient follow-up, thereby increasing operational efficiency and patient compliance[45]. - The company is advancing its digital transformation by integrating AI, internet, and big data technologies to reconstruct service models and business processes[112]. - The company plans to create an integrated online and offline service loop, enhancing patient convenience through upgraded internet hospital functionalities and AI-driven customer service[113]. Research and Development - The company published 103 academic papers and participated in the formulation of 13 industry standards in 2024, enhancing its academic influence[58]. - The company is conducting research on the effectiveness and safety of CLASS surgery for different stages of glaucoma[71]. - A new digital corneal reshaping lens is being developed to improve vision in patients with high myopia[72]. - Clinical studies are ongoing to evaluate the effectiveness of new surgical techniques for retinal detachment and chronic dacryocystitis[72]. - The number of R&D personnel increased to 93 in 2024, up from 76 in 2023, representing a growth of 22.37%[74]. - The company is investing in new product development, with a budget allocation of 500 million for R&D in the upcoming fiscal year[138]. Corporate Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations[127]. - The company has revised several management systems to enhance information disclosure, aiming for accurate and timely communication with investors[127]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[129]. - The company has a complete and clear ownership of assets, including land, properties, medical facilities, trademarks, and patents[129]. - The company has established an independent financial accounting system and maintains separate bank accounts from its controlling shareholders[129]. - The company has not faced any regulatory criticism regarding information disclosure during the reporting period[127]. Social Responsibility and ESG Initiatives - The company invested over 5 million yuan in social welfare initiatives, benefiting over 100,000 people in rural areas[176]. - The company provided over 21,000 pairs of free glasses and conducted more than 250 free surgeries for underprivileged children and elderly individuals[176]. - The company actively adheres to environmental regulations and has not faced any administrative penalties related to environmental issues during the reporting period[174]. - The company emphasizes the integration of ESG principles into its corporate culture and daily operations[175]. - The company is committed to sustainable development and social responsibility, balancing environmental, economic, and social values[175]. Shareholder Relations and Financial Management - The company announced a cash dividend of RMB 4.00 per 10 shares, totaling RMB 59,545,512.40, which accounts for 22.23% of the net profit attributable to shareholders for the reporting period[123]. - The company completed the acquisition of Dali Optometry Hospital in December 2024, enhancing its market share in the Yunnan region[120]. - The company has established a three-year shareholder return plan to balance performance growth with shareholder returns, promoting a sustainable development model[116]. - The company will not distribute profits in 2024 due to anticipated losses and to ensure sufficient funds for long-term development[164]. - The company has approved a plan to stabilize its stock price for three years post-IPO, triggered if the stock price closes below the audited net asset value per share for 20 consecutive trading days[193].

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-011 成都普瑞眼科医院集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）于2025年4月7 日召开第三届董事会第三十次会议和第三届监事会第二十一次会议，分别审议通 过了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用总 额不超过人民币25,000万元的闲置募集资金暂时补充流动资金，使用期限为自第 三届董事会第三十次会议审议通过之日起不超过12个月，到期归还至募集资金专 用账户。国泰海通证券股份有限公司（以下简称"保荐机构"）对该事项出具了 无异议的核查意见，本事项无需提交股东大会审议。现将相关情况公告如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意成都普瑞眼科医院股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]587号）同意注册，公司首次公开 发行人民币普通股（A股）股票37,404,762股，每股面值人民币1.00元，每股发 行价 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-008 特此公告。 成都普瑞眼科医院集团股份有限公司 董事会 二〇二五年四月八日 成都普瑞眼科医院集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）于近日收到国泰海通 证券股份有限公司（以下简称"国泰海通"）出具的《关于更换持续督导保荐代表人 的函》。国泰海通作为公司首次公开发行股票并在创业板上市的保荐机构，原指派田 卓玲女士和朱玉峰先生担任保荐代表人，负责保荐工作及持续督导工作，持续督导期 至2025年12月31日。 原保荐代表人朱玉峰先生因工作安排原因，无法继续从事对公司的持续督导工作。 为保证持续督导工作的有序进行，国泰海通现委派保荐代表人李沁杭先生（简历详见 附件）接替朱玉峰先生继续履行持续督导工作。 本次变更后，公司首次公开发行股票的持续督导保荐代表人为田卓玲女士和李沁 杭先生，持续督导期至中国证券监督管理委员会和深圳证券交易所规定的持续督导义 务结束为止。 本次变更持续督导保荐代表人的 ...